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GeneticMutations in the only known mammalian iron exporter ferroportin cause a rare iron overload disorder termed
ferroportin disease. Two distinct clinical phenotypes are caused by different disease mechanisms: mutations in
ferroportin either cause loss of iron export function or gain of function due to resistance to hepcidin, the peptide
hormone that normally downregulates ferroportin. The aim of the present study was to examine the disease
mechanisms of the thus far unclassiﬁed A69T and D181V ferroportin mutations. We overexpressed wild-type
and mutant ferroportin fused to green ﬂuorescent protein in human embryonic kidney cells and used a 59Fe-
assay, intracellular ferritin concentrations, confocalmicroscopy andﬂowcytometry to study iron export function,
subcellular localization and the responsiveness to hepcidin. While the A69T ferroportin mutation seems not to
affect the iron export function it causes dose-dependent hepcidin resistance. We further found that D181V mu-
tated ferroportin is iron export defective and hepcidin resistant, similar to the loss of function mutations A77D
and C367X. This indicates that intact iron export might be necessary for hepcidin-induced downregulation of
ferroportin. This hypothesis was investigated by studying the hepcidin response under modulation of iron avail-
ability. Incubation of wild-type ferroportin overexpressing cells with holo-transferrin increases the hepcidin ef-
fect whereas chelating extracellular ferrous iron causes hepcidin resistance. In this study we present data that
postulates to classify the D181V ferroportin mutation as loss of function and the A69T mutation as dose-
dependent hepcidin resistant and outline a possible causal link between iron export function and the hepcidin
effect.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Ferroportin disease is an inborn error of iron metabolism associated
with heterozygous gene defects in ferroportin [1]. Diagnosis is based on
the identiﬁcation of ferroportin mutations in patients with elevated
serum ferritin concentrations and increased iron storage in the liver
and or spleen and bone marrow. In previous studies, the age of presen-
tation is variable but is rarely made before the 3rd decade of life [2].he ‘Verein zur Förderung der
patologie an der Medizinischen
ck, Department of Medicine II—
6020 Innsbruck, Austria. Tel.:Since its ﬁrst description as an autosomal dominant iron storage disease
in a large Italian pedigree in 1999 [3], thatwas later shown to be associat-
edwith heterozygosity for the A77Dmutation in the ferroportin gene [4],
numerous disease-associated ferroportin mutations have been identiﬁed
(reviewed in [2]; for more recent reports of ferroportin mutations see
[5–10]). Ferroportin disease has highly variable clinical manifestations,
where a classical phenotype can be distinguished from a non-classical
phenotype on the basis of transferrin saturation and organ distribution
of iron overload. In classical ferroportin disease, hyperferritinemia is asso-
ciated with low-to-normal transferrin-saturation, and intolerance to iron
depletion by venesection; iron overload characteristically affects the liver,
spleen and bone marrow [11]. In contrast, the non-classical phenotype is
characterized by elevated serum ferritin concentrations and trans-
ferrin saturation. In non-classical ferroportin disease, excess iron is
predominantly stored in the liver, whereas the spleen and bone marrow
are unaffected [2].
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that causes iron overload in ferroportin disease, the functional conse-
quences of individual mutations have been investigated in a living cell
model of the cognate clinical disorder [12,13]. Accordingly, a geno-
type–phenotype correlation has been recognized in which the classical
phenotype is associatedwith, for example, the A77D ferroportin variant,
which induces loss of the iron export function [12]. Impaired iron export
function may result from failure to express functional ferroportin at the
plasma membrane or, where subcellular trafﬁcking is unimpaired, a
defective ‘pump mechanism’ for ferrous ions. Reports of intracellular
retention of A77D have recently been disputed by the ﬁnding that in a
modiﬁed and arguably more physiological overexpression model, the
A77D mutant ferroportin was correctly localized to the plasma mem-
brane [14,15]. The only mutation that did not localize correctly to the
plasma membrane is the ferroportin truncation mutation C367X,
which was used as a control mutant that was created in vitro and
has not been identiﬁed in a patient with iron overload [15]. In contrast,
the non-classical phenotype can be associated with ferroportin
mutations that reduce the afﬁnity of hepcidin for ferroportin thereby
impairing this action of hepcidin and thus partially mimicking a
hepcidin deﬁciency state. Well conducted genotype–phenotype corre-
lation studies have shown that Y64N, N114H, N144D and C326Y show
a severe phenotype with high transferrin saturation and deposition of
iron throughout the liver [13]. Under these circumstances, uncontrolled
duodenal iron absorption and unrestricted release of iron from macro-
phages occur.
Hepcidin is synthesized and secreted into the blood by hepatocytes
in response to high hepatic iron, elevated transferrin saturation andpro-
inﬂammatory stimuli such as interleukin-6 [16,17]. Hepcidin controls
plasma iron concentration and transferrin saturation by direct interac-
tion with ferroportin in a manner which induces its internalization
and degradation [18]. A cysteine residue at position 326 of ferroportin
is essential for the interaction with hepcidin and this is a plausible
explanation for the non-classical phenotype of patients harboring
mutations of this amino acid [19]. Although the non-classical disease
phenotype has been reported in patients with the N144H and Y64N
ferroportin mutations, when studied in vitro, the molecular interaction
between hepcidin and these ferroportin variants appears to be unaffect-
ed [19]. However, although these residues are not required for hepcidin
binding, the internalization is affected by the mutations Y64N and
N144H, where the latter exhibited partial hepcidin resistance [11].
In this study, we investigated the functional consequences of two
ferroportin mutations, D181V and A69T. While the former ferroportin
mutation is associated with classical ferroportin disease and loss of
iron export function, the latter was identiﬁed in a patient with a non-
classical disease phenotype.
2. Materials and methods
2.1. Plasmid construction
The mutations A69T, A77D, N144H, D181V, C326Y, and H507R were
introduced by site-directed-mutagenesis using the QuickChange Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA) into the pENTR221
vector (Invitrogen, Lofer, Austria) with the insert IOH26826. This is a
full length cDNA clone of human ferroportin. The resulting vectors as
well as the wild-type ferroportin pENTR221 vector were recombined
into the expression vector pcDNA/N-EmGFP-Dest (Invitrogen, using
the Gateway LR Clonase system). After recombination, the resulting
vector was designated pBABS, which has an open reading frame,
where mutant or wild type ferroportin is N-terminally fused to GFP
under the control of a CMV promoter. Alternatively, the pENTR221 vec-
tor with the ferroportin cDNA (IOH26826) was mutagenized to create a
read-through mutation of the stop codon, which was then recombined
with the expression vector pcDNA/N-EmGFP-Dest. The resulting vector
was designated pRASIL and encodes ferroportin N-terminally fused toGFP and a C-terminal V5-tag. For additional control experiments, the
C367Xmutant was cloned by inverse PCR: brieﬂy, the pENTR221 vector
(Invitrogen, Lofer, Austria) with the ferroportin cDNA insert IOH26826
was digested with HindIII, which is a single cutter. The resulting DNA
fragment was used as a template for a PCR reaction with the primers
5′-ACC CAG CTT TCT TGT ACA AAG-3′ and 5′-TTT TCG ACG TAG CCA
AGT AA-3′. Both primers were 5′-phosphorylated and the resulting
PCR product was puriﬁed and circularized by self-religation using a T4
ligase (Invitrogen, Lofer, Austria). This resulting construct was a
pENTR221 vector that contained a fragment of the ferroportin cDNA
containing codons 1 to 366 of the ferroportin open reading frame; this
truncation mutant was designated C367X. To generate expression
vectors for N-terminal fusion of truncated ferroportin with GFP and
N-terminal fusion with the V5 tag, this pENTR211 vector was
recombined with pcDNA/N-EmGFP-Dest as described above.
Cell culture, transfection and preparation of 59Fe labeled transferrin
were carried out as previously described [5].
2.2. 59Fe export & intracellular ferritin quantiﬁcation
Twelve hours after transfecting HEK (human embryonic kidney)
293T cells with plasmids encoding wild type or mutant ferroportin fu-
sion proteins (A77D, N144H, C326Y, A69T, and D181V) the effectene–
DNA-complexes were removed and 1 ml fresh medium supplemented
with 59Fe-holotransferrin corresponding to 200 kBq 59Fe was added to
each well. Four wells were left untransfected and served as controls.
After incubating overexpressing cells with 59Fe transferrin for 24 h,
cells were washed twice with PBS to remove unbound transferrin and
1 ml fresh medium was added. Six hours later, the culture medium
was removed and the pellet was collected to determine iron export
and iron retained by gamma counting. Each experiment was performed
in duplicate and repeated three times. The relative iron release from
wild type or mutant ferroportin overexpressing cells or untransfected
cells was calculated by correcting for the amount of 59Fe-uptake after
24 hour incubation and expressed as relative to wild-type iron export
for each individual experiment. To complement the results from 59Fe
export assays, cellular ferritin was quantiﬁed as a surrogate for intracel-
lular iron retention. For ferritin ELISA (Abnova, Walnut, CA, USA) cells
were seeded in 6-well plates before transfection with plasmids
encoding wild type or mutant ferroportin fusion proteins (A77D,
N144H, C326Y, A69T, D181V or C326X) for 24 h and incubated for 48
h in the presence of 2 g/l holo transferrin. Cells were then washed
with PBS and lysed by the addition of 100 μl lysis buffer (1% Triton X
100 in PBS with cOmplete Protease Inhibitor Cocktail Tablets (Roche,
Basel, Switzerland)). Total protein content was quantiﬁed and results
from the ferritin ELISA corrected for total protein content.
2.3. Flow cytometry
Twelve hours after transfection with wild type or A77D, N144H,
C326Y, A69T, or D181V mutant GFP-coupled ferroportin, 1 ml fresh
medium with or without hepcidin (Bachem, Bubendorf, Switzerland)
at a concentration of 500 nM was added to each well. Culture medium
was also supplemented with 2 mg/ml holo-transferrin (Scipac,
Sittingbourne, Kent, UK) to prevent cell death due to iron depletion in
this long experimental setting. After 56 h cells were harvested by
incubation with Cell Dissociation Solution (Sigma, Vienna, Austria) at
4 °C for 30 min. Flow cytometry analysis was then performed on a
FACSCalibur instrument (Becton Dickinson, Vienna, Austria). Mean
ﬂuorescence intensity was quantiﬁed using the 488 nm laser and a
530 ± 20 nm ﬁlter. Raw data were analyzed using the FACS analysis
software WinMDI 2.9 (copyright© Joseph Trotter). Hepcidin effects
were expressed as relative decrease in mean-ﬂuorescence intensity.
The results from three independently performed experiments are
shown.
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Fig. 1. Relative iron export via wild-type andmutant ferroportin. 59Fe exportedwithin 6 h
is expressed as a fraction of total 59Fe uptake and expressed relative to iron exported from
wild-type ferroportin overexpressing cells. Wild-type, N144H, C326Y and A69T mutant
ferroportin cause a more than 5-fold increase in iron export when compared to
untransfected cells. No such increase can be observed in A77D and D181V mutant
ferroportinoverexpressing cells.Mean and standard deviation of three independentlyper-
formed experiments are shown. Each experiment was performed in duplicates. *Indicates
p b 0.05 as tested by a MannWhitney U test when compared to wild type ferroportin ex-
pressing cells.
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tion complexes for 12 h and allowed to recover for 24 h in freshmedium
before incubation in serum-free medium and hepcidin at concentra-
tions of 10 nM, 70 nM and 500 nM. After incubation in the presence of
hepcidin for 4.5 h, cells were harvested and analyzed by ﬂow cytometry
as described above.
To quantify the effect of intra- and extracellular iron modulation on
hepcidin response, HEK293T cells were transfected with wild-type
ferroportin for 12 h before transfection complexes were removed and
cells were further incubated for 24 h in fresh medium supplemented
with 2 mg/ml holo-transferrin. Hepcidin effects were quantiﬁed by
ﬂow cytometry as described above after incubation of cells in serum
freemedium supplementedwith 70 nMhepcidin for 4.5 h. For iron che-
lator experiments, wild-type ferroportin overexpressing cells were in-
cubated in medium not supplemented with transferrin during the
24 hour recovery period after transfection. To assess the effect of iron
chelation on hepcidinmediated ferroportin degradation, the hydrophil-
ic ferrous iron chelator bathophenantroline disulfate (BPS) (Sigma,
Vienna, Austria) or the hydrophilic ferric iron chelator deferroxamine
(DFO) (Sigma, Vienna, Austria) at a 1mMconcentrationwas added dur-
ing the 4.5 hour incubation period with 70 nM hepcidin before ﬂuores-
cence intensity was quantiﬁed by ﬂow cytometry as indicated above.
2.4. Immuno-ﬂow cytometry
To quantify ferroportin at the plasma membrane, HEK293T
cells were transfected with the pRASIL vector, where ferroportin is
N-terminally fused to GFP and C-terminally fused to the V5-sequence
tag. Wild-type as well as A77D, N144H, C326Y, D181V, A69T and
C367X ferroportin mutants were overexpressed as V5 fusion proteins.
Thirty six hours after transfection cells were dissociated as de-
scribed above and incubated with a primary mouse anti-V5 antibody
(Invitrogen, Lofer, Austria) or an IgG2a isotype control antibody (Abcam,
Cambridge, UK) for 1 h. After washing, cells were incubated with a
secondary goat anti-mouse PE labeled antibody (Abcam, Cambridge,
UK) for 45 min. The increase in red ﬂuorescence was quantiﬁed on a
FACSCalibur instrument using the 488 nm laser for excitation and a
585 ± 21 nm ﬁlter for ﬂuorescence detection (Becton Dickinson,
Vienna, Austria). Raw data were analyzed with the CellQuest software
(Becton Dickinson).
2.5. Confocal microscopy
One day after transfection as described above, HEK293T were
analyzed by confocal microscopy as previously described [20].
3. Results
3.1. D181V causes reduced iron export function while A69T does not impair
iron export
To study the functional consequences of ferroportin mutations we
overexpressed the hitherto unclassiﬁed D181V and A69T ferroportin
mutants or ferroportin harboring the control mutations A77D, N144H,
C326Y orwild-type ferroportin in HEK293T cells. To evaluate the impact
of ferroportin mutations on its iron export function, we quantiﬁed
exported and retained 59Fe in transfected cells and calculated the rela-
tive iron export, which we compared with iron exported by cells over-
expressing wild-type ferroportin (Fig. 1A). Overexpression of wild
type ferroportin in HEK293T cells results in an approximately 5-fold in-
crease in the rate of iron export when compared withmock transfected
cells. Cells overexpressing the A69Tmutant ferroportin exported iron at
a rate comparable to that of wild-type ferroportin expressing cells. The
D181V ferroportinmutant is associatedwith an apparent loss of iron ex-
port activity. Cells overexpressing the control mutations N144H and
C326Y show normal iron export function in this assay, which is incontrast to cells expressing the control mutation A77D. These ﬁndings
were conﬁrmed by quantiﬁcation of intracellular ferritin by ELISA in
cells loaded with iron by incubation in the presence of 2 g/l human
holo-transferrin. Fig. 1B shows that intracellular ferritin concentrations
in HEK293T cells expressing A77D, D181V or the truncation C367Xmu-
tant are comparable to the ferritin concentration in extracts from
untransfected HEK293T cells. In contrast, ferritin concentration in cells
expressing the A69Tmutant is decreased to a concentration comparable
to that of wild type ferroportin expressing cells. Taken together these
results show that the D181V ferroportin mutation causes reduced iron
export function, whereas the pathogenic mechanism of the A69Tmuta-
tion is not apparent from these experiments.
3.2. All studied mutations localize to the plasma membrane
A possible mechanism of how ferroportinmutationsmight cause re-
duced iron export is intracellular retention of mutant ferroportin. Only
ferroportin correctly localized to the plasmamembrane is able to export
iron from the cell. To address this question we investigated the subcel-
lular localization of wild-type and mutant ferroportin by confocal mi-
croscopy and immuno-ﬂow cytometry (Fig. 2). As shown in Fig. 2A,
ferroportin fused with GFP localized to the plasma membrane in cells
overexpressing either wild-type ferroportin or the A69T, N144H,
C326Y, D181V and the A77D mutants of ferroportin. In addition, a vari-
able amount of intracellularly retained ﬂuorescence is present. To con-
ﬁrm that all investigated ferroportin mutants can trafﬁc to the plasma
WT A77D N144H
C326Y A69T D181V
A
B
A69T A77D C326Y
C367X D181V N144H
WT
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Fig. 2. Plasma membrane localization of wild-type and mutant ferroportin. (A) Confocal microscopy reveals prominent membrane ﬂuorescence of wild-type and A77D, N144H, C326Y,
A69T and D181V mutants of GFP-ferroportin. (B) In ﬂow-cytometry studies, the addition of an anti-V5 primary antibody and a secondary PE labeled antibody to non-permeabilized
GFP-ferroportin-V5 overexpressing cells causes an increase in red ﬂuorescence (black line) against the background signal (gray histogram). This conﬁrms that wild-type and A77D,
N144H, C326Y, A69T and D181V ferroportin mutants localize to the plasma membrane.
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1410 R. Praschberger et al. / Biochimica et Biophysica Acta 1842 (2014) 1406–1412membrane, we quantiﬁed plasma membrane ferroportin with an addi-
tional assay. For this aim, cells were transfected with a plasmid vector
encoding ferroportin which is N-terminally fused with GFP and has a
C-terminal V5-tag. Fluorescence was quantiﬁed by ﬂow cytometry in
non-permeabilized wild-type and mutant GFP-ferroportin-V5 overex-
pressing cells by indirect immunoﬂuorescence using a PE-goat anti
mouse antibody and a V5 antibody. As a control the ferroportin trunca-
tionmutation (C367X)was expressed and also analyzed by FACS,which
shows that this truncated ferroportin variant does not trafﬁc to the plas-
ma membrane. As shown in Fig. 2B all other investigated ferroportin
variants are expressed at the cell surface as shown by immune ﬂow cy-
tometry. Histogram data show that the concentrations of ferroportin
expressed at the cell surface are comparable between cells expressing
different mutations. This ﬁnding strongly supports the concept that
the apparent reduction in iron export function of D181V and A77Dmu-
tant ferroportin is caused by a defective pump mechanism and not by
intracellular retention.-60
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Fig. 3.Differences in dose-dependent downregulation of ferroportinmutants by hepcidin.
(A) C326Y, A77D, and D181V ferroportin mutants cause a decreased hepcidin-effect after
incubation for 56 hwith 500 nMhepcidin. A69T and N144H ferroportinmutants are com-
parable to wild-type ferroportin. (B) At a hepcidin-concentration of 70 nM or 10 nM for a
4.5 hour incubation period, the hepcidin effect is reduced to approximately 50% when
compared with the hepcidin effect in wild-type ferroportin expressing cells. (C) Incuba-
tion of cells with 2 mg/ml holotransferrin increases, while chelating extracellular ferrous
iron decreases the hepcidin-effect. Mean and standard deviation of three independently
performed experiments are shown. *Indicates p ≤ 0.05 as tested by a Mann Whitney3.3. Analysis of hepcidin resistance in different ferroportin variants
To test the response of wild-type and D181V, A69T, A77D, N144H
and C326Y ferroportin mutants to hepcidin we used a ﬂow-cytometry
assay. We quantiﬁed the decrease in mean ﬂuorescence intensity
(MFI) of HEK293T cells overexpressing GFP-ferroportin after incubation
with 500 nM hepcidin for 56 h. We used a long incubation time and a
high hepcidin concentration to study maximal internalization and deg-
radation. To prevent cells from dying due to iron depletion in this long
experimental setting we incubated the transfected cells with 2 mg/ml
holo-transferrin. As shown in Fig. 3A the addition of hepcidin in a
500 nM concentration for 56 h causes approximately a 55% decrease
of MFI in wild-type ferroportin overexpressing cells. A comparable ef-
fect is found in A69T mutant ferroportin transfected cells whereas the
loss of function ferroportin mutants D181V and A77D and the non-
classical control mutation C326Y show a signiﬁcantly reduced response
to hepcidin. The response of N144H mutant ferroportin to hepcidin is
slightly reduced when compared to wild type overexpressing cells. To
further investigate the response of the disease associated ferroportin
mutations A69T and N144H to hepcidin, lower hepcidin concentrations
and shorter incubation time were used (4.5 h and three hepcidin con-
centrations — 500 nM, 70 nM, 10 nM). When incubated with 500 nM
hepcidin for 4.5 h no difference in the reduction of MFI in wild-type
and A69T and only a slightly reduced effect in N144H ferroportin was
apparent (Fig. 3B). However, when we used reduced hepcidin concen-
trations of 70 nM or 10 nM for 4.5 h the hepcidin-response of A69T
and N144H mutant ferroportin overexpressing cells was only half of
that observed in wild-type ferroportin transfected cells. Therefore we
conclude that the ferroportin mutants A69T and N144H are partially
hepcidin resistant.U test when compared to wild type ferroportin expressing cells.3.4. Iron is required for hepcidin dependent ferroportin internalization
Our ﬁnding, that the loss of function mutations D181V and A77D
also confer a reduced response to hepcidin led us to the hypothesis,
that iron transport might be necessary for hepcidin mediated internali-
zation and degradation of ferroportin. To further investigate this ques-
tion we studied the hepcidin-effect with or without prior incubation
with 2 mg/ml holo-transferrin and in the presence of the ferrous iron
chelator bathophenantroline disulfate (BPS) or the ferric iron chelator
deferoxamine (DFO). As shown in Fig. 3C, signiﬁcantly more GFP-
ferroportin is internalized and degraded in HEK293T cells, which were
incubated with holo-transferrin. In contrast, extracellular ferrous iron
chelation causes hepcidin-resistance while ferric iron chelation does
not. These ﬁndings show that iron is required for hepcidin-dependent
ferroportin internalization.3.5. D181V causes the classical, A69T the non-classical disease phenotype
We identiﬁed the D181Vmutation in an English family with autoso-
mal dominant inherited hemochromatosis (Fig. 4A). The proposita (II.3)
presented at aged 52 with a ferritin of 1040 μg/l and a 24% transferrin
saturation. Magnetic resonance imaging (MRI) demonstrated both he-
patic and splenic iron overload (Fig. 4B). Homozygosity for p.C282Y of
the HFE gene was excluded. One of her two sons (III.1) was found to
have a ferritin of 932 μg/l and 24% transferrin saturation — the D181V
mutation was conﬁrmed. Her other son (III.2) had a ferritin of 228 μg/l
with absence of D181V. Two siblings of the proposita had been diag-
nosed with iron overload and venesected — both harbored the D181V
mutation. The brother (II.4) had in fact developed hepatocellular carci-
noma and underwent liver transplantation. A liver biopsy from the sis-
ter (II.1) was reported as demonstrating slight hepatic but prominent
I.1 I.2
II.1
III.
1
II.2 II.3 II.4
III.2
A
B
C
Fig. 4. Pedigree and abdominal MRI of the index case of the family affected by ferroportin
disease associated with the D181V ferroportin mutation. (A) Pedigree showing inheri-
tance pattern compatible with autosomal dominant transmission of hyperferritinemia.
Shaded boxes represent those diagnosed with evidence of iron overload. Boxes marked
with a small dot in the lower right quadrant indicate that this family member was not ge-
netically tested. The index case is indicated by an arrow. (B) The abdominal MRI of the
index case shows the reduced signal of the liver, spleen and bonemarrow,which indicates
iron overload in these organs. (C) Perls' stained liver biopsy showing hepatocellular iron
accumulation compatible with non-classical A69T ferroportin disease.
Reprinted fromMacSween's Pathology of the Liver, 6th Edition, Disorders of iron overload,
Paterson AC, Pietrangelo A., page 271 copyright 2012 with permission from Elsevier [21].
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the D181Vmutation is one of classical ferroportin disease. In contrast, a
patient from an Italian family harboring the A69T mutation presented
with non-classical ferroportin disease: the liver biopsy showed predom-
inantly iron deposition in hepatocytes (Fig. 4C) [21]. The classical
disease phenotype of the family with the D181V mutation and thenon-classical clinical disease of the A69T family are in linewith the clas-
sical, loss of function diseasemechanismwhichwe observed in vitro for
the D181V mutation and the non-classical, hepcidin-resistance mecha-
nism for the A69T mutation.
4. Discussion
The aim of the present study was to functionally categorize the
ferroportin variants D181V and A69T. On the basis of our ﬁnding that
the D181V ferroportin mutant was associated with reduced iron export
we propose to classify this protein as a loss-of-function variant — a
proposition which accords with the classical expression of disease in
the affected members of the pedigree. Cremonesi et al. [22] ﬁrst report-
ed this mutation in an Italian family who also presented with the classi-
calmanifestations of ferroportin disease.We further show that the A69T
mutant ferroportin is less responsive to hepcidin at low hormone con-
centrations. Taken together with the fact that themutation was initially
found in patients with hepatocellular iron overload, A69T was assigned
to an association with ‘non-classical’ ferroportin disease [21]. Differen-
tial effects of hepcidin in A69T andwild-type ferroportin overexpressing
cells were not found when cells were incubated for 56 h with 500 nM
hepcidin. In previous studies high hepcidin-concentrations and long in-
cubation times were used to study the effect of exogenous hepcidin on
mutant ferroportin [13,19]. More recent studies showed that lower con-
centrations of hepcidin and shorter incubation times are sufﬁcient to in-
duce internalization and degradation of ferroportin [18,23,24]. The
reported reference concentrations for hepcidin in plasma are approxi-
mately 10 nM for healthy men and postmenopausal women and thus
far lower than the 500 nM concentration formerly applied in the
in vitro cell culture studies [25,26]. We contend that such concentra-
tions are supraphysiological and would be found in plasma only under
extreme and exceptional conditions. However, in overexpression
models such high concentrations may be necessary to effectively inter-
nalize high ferroportin levels in these systems. Based on our ﬁndings it
will be interesting to study the effect of lower hepcidin concentrations
on the internalization and degradation of the hepcidin variants N144D
and Q248H, which have previously been reported as ‘partially hepcidin
resistant’ [11].
Of note, our experiments showed that D181V & A77D ferroportin
mutants are also resistant to hepcidin, despite the fact that the protein
localizes normally to the plasma membrane as shown in the V5-tag
immuno-FACS assay. Thus hepcidin resistance cannot be ascribed to
faulty trafﬁcking to the plasmalemma. An alternative explanation for
the hepcidin resistance that was observed in the loss-of-function muta-
tions A77D and D181V would be that intact iron export function is re-
quired for hepcidin binding. In support of this hypothesis, we found
that chelation of ferrous iron was associated with a decreased hepcidin
effect, whereas chelation of ferric iron had no effect on the hepcidin re-
sponse. In contrast, when iron stores are augmented, the hepcidin effect
of ferroportin increases.
From these ﬁndings, we conclude that chelatable ferrous iron, possi-
bly within the ferroportin channel, is required for hepcidin to exert its
effect on ferroportin. In accordance with this hypothesis Kono et al.
found that co-overexpression of ferroportin and GPI-Cp causes partial
hepcidin-resistance [27]. This could be due to the fact that ferrous iron
is rapidly removed from ferroportin by oxidation through the co-
expressed ferroxidase. Furthermore, hepcidin itself has been suggested
to bind iron [28–30]. Based on these ﬁndings, one could speculate that
hepcidin can only bind to ferroportin while it is actively pumping
iron. In such a hypothetical scenario, the interaction of hepcidin and
ferroportin could involve direct binding of hepcidin to iron in addition
to protein–peptide interactions.
Our ﬁnding that C-terminal V5-tagged ferroportin could be
immunostained in non-permeabilized cells supports the concept
that the C-terminus is located extracellularly. While some groups
found that the C-terminus was accessible for antibodies only in
1412 R. Praschberger et al. / Biochimica et Biophysica Acta 1842 (2014) 1406–1412permeabilized cells [14,15,31], others detected the C-terminus also
in non-permeabilized cells [12,13,32]. The results obtained with
immuno-ﬂow cytometry of non-permeabilized cells show compara-
ble membrane-associated ﬂuorescence in cells expressing wild type
and mutant ferroportin.
In conclusion, our results provide the link between the disease-
associated ferroportin mutations D181V and A69T and altered function
of mutant ferroportin in vitro. The observed functional difference in our
model system is in line with the diverse clinical manifestations of
ferroportin disease that have been reported. The observation that the
hepcidin effect on ferroportin can bemodulated by controlling the avail-
ability of iron supports the concept that hepcidin targets only those
ferroportin molecules that are actively pumping iron. These discoveries
could reﬁne our understanding of ferroportin as a hepcidin receptor and
permit further elucidation of the genotype–phenotype correlation in
ferroportin disease.
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